Switzerland-based SOPHiA Genetics (Nasdaq: SOPH), an AI-native healthcare technology company, announced the closing of an underwritten public offering of ordinary shares, raising USD 57.5 million in gross proceeds to fund the continued expansion of its SOPHiA DDM platform and broader commercial operations. The offering is notable for the extent of investor demand: the transaction was oversubscribed, prompting underwriters to fully exercise their option to purchase additional shares, lifting total proceeds above the initial USD 50 million target announced at pricing on June 16, 2026.
The offering comprised 12,104,900 ordinary shares priced at USD 4.75 per share, including 1,578,900 shares issued upon full exercise of the underwriters' overallotment option. All shares were sold by SOPHiA; no selling shareholders participated. TD Cowen acted as lead book-running manager, with Guggenheim Securities serving as book-running manager and BTIG and Craig-Hallum acting as lead managers. No specific institutional investors were identified by name in the offering documents.
SOPHiA is headquartered in Rolle, Switzerland, with a US presence in Boston, Massachusetts. The company operates SOPHiA DDM, an AI-driven platform that analyzes complex genomic and multimodal data to generate real-time clinical insights for a global network of hospital, laboratory, and biopharma institutions. The platform is positioned as infrastructure for data-driven medicine rather than a single-indication diagnostic product, giving it broad applicability across oncology and rare disease workflows.
The company does not operate a conventional drug pipeline. Its commercial model centers on platform adoption across institutional users globally, with revenue generated through platform access, analytical services, and biopharma partnerships. Proceeds from the offering are directed toward general corporate purposes consistent with expanding that commercial footprint, though the company has not specified discrete milestones tied to this capital raise.
On the business development side, SOPHiA GENETICS has been active in forging partnerships that extend the DDM platform's reach. In September 2025, the company entered a strategic collaboration with Myriad Genetics to jointly develop and commercialize a global liquid biopsy companion diagnostic test, with an initial focus on MSK-ACCESS powered by SOPHiA DDM, a ctDNA-based test developed in collaboration with Memorial Sloan Kettering Cancer Center. That deal positions SOPHiA GENETICS as a participant in the companion diagnostics market, where demand is driven by the proliferation of targeted oncology therapies requiring biomarker-matched patient selection. In November 2025, the company announced a collaboration with Element Biosciences to integrate sequencing technology with its AI analytics capabilities. Earlier deals include a 2024 tri-party collaboration with Microsoft and NVIDIA focused on whole genome sequencing analytical solutions, and a partnership with Precision for Medicine signed in April 2025 to embed the DDM platform in clinical trial and CRO services.